Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38888
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | VANDORMAEL, Patrick | - |
dc.contributor.author | PUES, Astrid | - |
dc.contributor.author | SLEURS, Ellen | - |
dc.contributor.author | LIESENBORGS, Jori | - |
dc.contributor.author | Verschueren, P. | - |
dc.contributor.author | SOMERS, Veerle | - |
dc.date.accessioned | 2022-11-21T08:05:08Z | - |
dc.date.available | 2022-11-21T08:05:08Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-11-03T17:33:39Z | - |
dc.identifier.citation | ANNALS OF THE RHEUMATIC DISEASES, 81 , p. 299 | - |
dc.identifier.uri | http://hdl.handle.net/1942/38888 | - |
dc.description.abstract | Scientific Abstracts 299 ANOSIM). Detailly, at the genera level, IIM patients had a higher abundance of Ente-rococcus, Veillonella, Streptococcus, et al. and a lower abundance of Roseburia, Lachnospira, Klebsiella, et al(Figure 1D, p < 0.05). In IIM patients, Fusobacteriota correlated positively with the ratio of Th1 cells (Figure 1E, p < 0.01), and there was a significant positive correlation between Synergistota and B lymphocyte (Figure 1E, p < 0.01). Besides, Euryarchaeota and Cyanobacteria were both positively and significantly related to IL-6, IFN-γ and C-reactive protein (CRP) (Figure 1E, p < 0.001). Conclusion: Richness and diversity of intestinal flora in IIM patients were impaired, which might participate in the pathogenesis of IIM by disturbing lym-phocyte subpopulations and cytokines. Regulating intestinal flora and restoring homeostasis might become a critical therapeutic methods of IIM. REFERENCES: [1] Xu Y, Sun J, Wan K, et al. Multiparametric cardiovascular magnetic resonance characteristics and dynamic changes in myocardial and skeletal muscles in idiopathic inflammatory cardiomyopathy. J Cardiovasc Magn Reson 2020;22(1):22. | - |
dc.description.sponsorship | Patrick Vandormael: None declared, Astrid Pues: None declared, Ellen Sleurs: None declared, Jori Liesenborgs: None declared, Patrick Verschueren Speakers bureau: Eli Lilly, MSD, Galapagos, Roularta, Consultant of: Galapagos, Gilead, Pfizer, Sidekick Health, Eli Lilly, Nordic Pharma, ABBVIE, Celltrion, BMS, UCB, Grant/research support from: Holder of the Pfizer Chair Management of Early Rheumatoid Arthritis at KU Leuven, Veerle Somers Grant/ research support from: research grant from Pfizer. | - |
dc.language.iso | en | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Novel antibody biomarkers that predict failure to achieve early and sustained disease remission or low disease activity after intensive first-line therapy in rheumatoid arthritis | - |
dc.type | Journal Contribution | - |
dc.identifier.spage | 299 | - |
dc.identifier.volume | 81 | - |
local.format.pages | 1 | - |
local.bibliographicCitation.jcat | M | - |
local.publisher.place | BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.doi | 10.1136/annrheumdis-2022-eular.2388 | - |
dc.identifier.isi | 000850279001084 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Vandormael, P.; Pues, A.; Sleurs, E.; Somers, V.] Hasselt Univ, Biomed Res Inst, Immunol & Infect, Diepenbeek, Belgium. | - |
local.description.affiliation | [Liesenborgs, J.] Hasselt Univ, Expertise Ctr Digital Media, Computat Sci, Diepenbeek, Belgium. | - |
local.description.affiliation | [Verschueren, P.] Univ Hosp Leuven, KULeuven, Rheumatol, Leuven, Belgium. | - |
local.uhasselt.international | no | - |
item.contributor | VANDORMAEL, Patrick | - |
item.contributor | PUES, Astrid | - |
item.contributor | SLEURS, Ellen | - |
item.contributor | LIESENBORGS, Jori | - |
item.contributor | Verschueren, P. | - |
item.contributor | SOMERS, Veerle | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | VANDORMAEL, Patrick; PUES, Astrid; SLEURS, Ellen; LIESENBORGS, Jori; Verschueren, P. & SOMERS, Veerle (2022) Novel antibody biomarkers that predict failure to achieve early and sustained disease remission or low disease activity after intensive first-line therapy in rheumatoid arthritis. In: ANNALS OF THE RHEUMATIC DISEASES, 81 , p. 299. | - |
crisitem.journal.issn | 0003-4967 | - |
crisitem.journal.eissn | 1468-2060 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
299.1.full.pdf | Published version | 283.15 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.